Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Don't let "early stage" fool you. A new study finds that patients initially diagnosed with stage I melanoma who later experience recurrence face worse survival outcomes and higher tumor burden than those first diagnosed at stage II or III. Despite a longer relapse-free period, these patients are more likely to develop brain metastases and multiple metastatic sites when the disease returns.
When melanoma comes back, the original stage matters — but not in the way you might expect. A registry-based study published in the Journal of the American Academy of Dermatology found that patients initially diagnosed with stage I melanoma who later developed unresectable or advanced disease had significantly shorter overall survival (19.8 months) compared to those first diagnosed at stage IIA (60.1 months), IIB/C (32.6 months), or stage III (43.0 months). The analysis drew from the Spanish Melanoma Registry (GEM1801), which enrolled 1,302 patients, with 365 eligible for this analysis.
While stage I patients enjoyed a longer relapse-free interval (median 52 months vs. 25–30 months for higher stages), the disease came back harder. They were more likely to present with a heavier metastatic burden, more frequent brain involvement, and elevated lactate dehydrogenase levels — all markers of aggressive disease. Notably, once tumor burden and other prognostic factors were accounted for, initial stage was no longer an independent survival predictor.
By the Numbers:
Why it matters: This study challenges the assumption that early-stage melanoma is inherently low-risk. Clinicians may need to rethink follow-up protocols for stage I patients, as delayed but aggressive recurrence can significantly worsen outcomes.